Eli Lilly (NYSE: LLY), Novo Nordisk And Novartis Bet On Discovery Platforms Over Late-Stage Pipeline Assets
Big pharma’s dealmaking appetite remains strong in 2026, but the strategic logic has shifted decisively toward platform access…
Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
Novartis and Eli Lilly have opposed a petition before the Kerala High Court seeking government intervention to make…
Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset
Exclusive agreement adds BoomRay’s preclinical RLT programme to Novartis’ oncology pipeline, with potential milestone payments of up to…
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
On Thursday, Eli Lilly and China’s InnoCare Pharma signed a research collaboration and license covering up to five…
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials…
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials…
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single…
A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team
On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called…
A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team
On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called…
Fangda, MoFo steer USD900m Boomray-Novartis licence agreement
Biotechnology company Boomray Pharmaceuticals has entered into an exclusive global licence agreement with Novartis for a preclinical radioligand…
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
Investing.com — HSBC adjusted ratings and target prices across its biopharma coverage, citing “a lower sector additional risk…
Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline
Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset.…